Narmafotinib
Narmafotinib (AMP-945) is an orally active inhibitor of the enzyme focal adhesion kinase (FAK, KD=0.21 nM) . Narmafotinib inhibits autophosphorylation of 397Y-FAK in MDA-MB-231 cells with an IC50=7 nM and exhibits low general cellular toxicity (IC50=2.7 μM, MDA-MB-231 cells) . Narmafotinib can be used for anti-cancer study[1].
Product Specifications
CAS Number
1393653-34-3
Product Name Alternative
AMP-945
UNSPSC
12352005
Target
FAK
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/narmafotinib.html
Concentration
10mM
Purity
99.86
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(CC1=C(CCC2=NC(NC3=CC=C(C4CCN(CC4)C)C=C3OC)=NC=C2C(F)(F)F)C=CC=C1)N
Molecular Formula
C28H32F3N5O2
Molecular Weight
527.58
References & Citations
[1]Amplia Therapeutics completes single-dose study of AMP945|[2]Street I, et al. Abstract LB-308: combination of CTx-0294945 a highly selective inhibitor of focal adhesion kinase with bevacizumab in pre-clinical models of breast cancer[J]. Cancer Research, 2012, 72 (8_Supplement) : LB-308-LB-308.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
HA751275 100 µL
Eph receptor A2 Recombinant Rabbit monoclonal Antibody
Sign In for Pricing
View Details 
